• Vaccine Name: Marburg virus glycoprotein expressed by baculovirus recombinants
• Target Pathogen: Marburg Virus
• Target Disease: Hemorrhagic fever
• Vaccine Ontology ID: VO_0004128
• Type: Live, attenuated vaccine
• Antigen: The full-length and truncated GP were expressed by baculovirus recombinants (Hevey et al., 1997). Both antigens were abundantly glycosylated with both N- and O-linked glycans.
• NP from Marburg virus Musoke gene engineering:
  • Type: Recombinant protein preparation
  • Description: This Musoke NP gene was amplified by PCR, and subcloned to create MARV adenovirus vaccine targeted against the Musoke strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click Here.
• GP from Musoke Marburgvirus gene engineering:
  • Type: Recombinant protein preparation
  • Description: This Musoke GP gene was amplified by PCR, and subcloned to create MARV adenovirus vaccine targeted against the Musoke strain of MARV (Wang et al., 2006).
  • Detailed Gene Information: Click Here.
• Preparation: MBGV glycoprotein (GP) was expressed in Baculovirus recombinants either as a slightly truncated product secreted into medium or a complete, cell-associated molecule(Hevey et al., 1997).
• Virulence: Irradiated MBGV antigen was protective against two MBGV strains (Musoke and Ravn). The recombinant truncated glycoprotein did elicit protection against challenge with the MBGV isolate from which it was taken(Hevey et al., 1997).

Guinea pig Response

• Host Strain: Strain 13 and Hartley
• Vaccination Protocol: Groups of animals were challenged with Ravn and Musoke strains, and ELISA titers were use to measure response 28 days after challenge (Hevey et al., 1997).
• Immune Response: Irradiated, gradient-purified virus completely protected Strain 13 from both Ravn and Musoke MBGV strains (Hevey et al., 1997).
• Challenge Protocol: Guinea pigs (Hartley and Strain 13) were divided into groups and injected with irradiated GP or recombinant GP. ELISA titers measureing response were taken 2 days before challenge and 28 days after for comparison (Hevey et al., 1997).
• Description: Animals that recieved the MBGV antigen (strainRavn) had a lower survival rate than those challenged with the Musoke strain(Hevey et al., 1997).